CRM197, Diphtheria Toxin Mutant
Catalog No : USB-208815
587.37€
0.00€
Shipping cost plus VAT not included , delivery in 7-14 business days
| Product name | CRM197, Diphtheria Toxin Mutant | ||
|---|---|---|---|
| Catalog No | USB-208815 | ||
| Supplier’s Catalog No | 208815 | ||
| Supplier | US Biologicals | ||
| Source antigen | Diphtheria Toxin | ||
| Reactivity | |||
| Cross reactivity | |||
| Applications | |||
| Molecular weight | 58 | ||
| Storage | -20°C | ||
|---|---|---|---|
| Other names | |||
| Grade | Highly Purified | ||
| Purity | Highly Purified (~95%) | ||
| Form | Supplied as a lyophilized powder in 10mM phosphate buffer, pH 7.5, 1mM EDTA, 5% lactose. Reconstitute with sterile ddH2O. | ||
| Reactivity life | 12 months | ||
| Note | For reserch purpose only | ||
| Purity | Highly Purified (~95%) | ||
| Description | Diphteria is a localized infection of mucous membranes or skin caused by toxigenic strains of CORYNEBACTERIUM DIPHTHERIAE. It is characterized by the presence of a pseudomembrane at the site of infection. DIPHTHERIA TOXIN, produced by C. diphtheriae, can cause myocarditis, polyneuritis, and other systemic toxic effects. Diphtheria toxin is an exotoxin secreted by Corynebacterium diphtheriae, the pathogen bacterium that causes diphtheria. Diphtheria toxin is a single polypeptide chain of 535aa (~63kD) consisting of two subunits linked by disulfide bridges. An ADP-ribosylating polypeptide produced by CORYNEBACTERIUM DIPHTHERIAE that causes the signs and symptoms of DIPHTHERIA. It can be broken into two unequal domains: the smaller (24 kda), catalytic A domain is the lethal moiety and contains MONO(ADP- RIBOSE) TRANSFERASES which transfers ADP RIBOSE to PEPTIDE ELONGATION FACTOR 2 thereby inhibiting protein synthesis; and the larger B domain (39kD) that is needed for entry into cells. Binding to the cell surface of the less stable of these two subunits allows the more stable part of the protein to penetrate the host cell. It catalyzes the ADP-ribosylation of eukaryotic elongation factor-2 (eEF2), inactivating this protein. It does so by ADP-ribosylating the unusual aminoacid diphthamide. In this way, it acts as a RNA translational inhibitor. The exotoxin A of Pseudomonas aeruginosa uses a similar mechanism of action. Diphtheria toxin is extraordinarily potent.[1] The lethal dose for humans is about 0.1ug of toxin per kg of bodyweight. A massive release of toxin into the body will likely cause lethal necrosis of the heart and liver. Diphtheria Toxoid is formaldehyde-inactivated toxin of Corynebacterium diphtheriae. It is generally used in mixtures with TETANUS TOXOID and PERTUSSIS VACCINE; (DTP); or with tetanus toxoid alone (DT for pediatric use and Td, which contains 5- to 10-fold less diphtheria toxoid, for other use). Diphtheria toxoid is used for the prevention of diphtheria; DIPHTHERIA ANTITOXIN is for treatment. Mutant forms of diphtheria toxin (DT), cross-reactive material 197 (CRM197) is a non-toxic DT mutant containing a lesion in the A chain blocking ADP-ribosylation. CRM results from a single base change in the structural gene resulting in the substitution of glutamic acid for glycine. While CRM shows no enzymatic activity, it is immunologically indistinguishable from diphtheria toxin. In its applications, CRM 197 is similar to diphtheria toxoid. CRM has the advantage of being a well defined protein in contrast to formaldehyde treated toxin (toxoid) which is non-specifically cross linked and subject to rearrangement. CRM functions as a carrier for polysaccharides and haptens making them immunogenic. Source: CRM197, from mutant Diphtheria Toxin (DT) Applications: Suitable for use in ELISA, Western Blot, Antibody Titration or as Control Protein for Adjuvant. Other applications not tested. Recommended Dilution: Optimal dilutions to be determined by the researcher. Storage and Stability: Lyophilized powder may be stored at -20°C. Reconstitute with sterile ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 6 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. | ||
Product Details
© 2020 Imugex All Rights Reserved